DGAP-News: STRATEC enters into supply agreement with One Lambda


STRATEC Biomedical Systems AG / Alliance

09.01.2008 

Release of a Corporate-announcement, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

STRATEC enters into supply agreement with One Lambda

Birkenfeld, January 9, 2008

STRATEC Biomedical Systems AG, Birkenfeld, Germany, announces that it will
enter into a supply and development agreement with One Lambda Inc., Canoga
Park, California, USA, for an automated sample preparation system called
LABXpress. LABXpress will be developed to automate One Lambda’s LABScreen
and LABType assays.

Initially, the LABXpress system will address the need for high throughput
screening of blood samples by blood banks concerned about the presence of
antibodies directed towards Human Leukocyte Antigens (HLA) and Human
Neutrophil Antigens (HNA) in blood products. Recent research suggests that
HLA and HNA antibodies may be contributing factors in Transfusion Related
Acute Lung Injury (TRALI), and these tests will allow blood centers to
further investigate their role.

High volume solid organ and bone marrow transplant centers will also
benefit from LABXpress’ hands-free capabilities. HLA laboratory personnel
will be able to load samples and LABType or LABScreen reagents and walk
away as samples are processed for HLA typing and/or antibody screening
respectively. Upon completion of sample processing, the LABXpress
automatically transfers the samples to the fully integrated LABScan 100
flow analyzer utilizing Luminex xMAP technology. Finally, the acquired data
will be analyzed using One Lambda’s HLA Fusion software.

Both companies will enter into a development and supply cooperation for a
fully automated screening system to meet the demands of high throughput
laboratories in this market.
About One Lambda

One Lambda Inc. (http://www.onelambda.com) is the world wide leader in HLA
typing and antibody detection assays. One Lambda is known for its
commitment to quality, service and innovation. One Lambda develops and
distributes several lines of histocompatibility (HLA) typing and antibody
detection tests utilizing serological, molecular, elisa, flow, and luminex
xMAP technologies. One Lambda also manufactures laboratory instrumentation
and computer software that are used to simplify and automate testing
procedures and final test evaluations.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC
NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin
International Inc., a subsidiary of Sanguin International Ltd.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916 190
Fax: +49 7082 7916 999
E-Mail: ir@stratec-biomedical.de
DGAP 09.01.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       STRATEC Biomedical Systems AG
              Gewerbestraße 37
              75217 Birkenfeld
              Deutschland
Phone:        +49 (0)7082 7916 0
Fax:          +49 (0)7082 7916 999
E-mail:       info@stratec-biomedical.de
Internet:     www.stratec-biomedical.de
ISIN:         DE0007289001
WKN:          728900
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Stuttgart, München, Düsseldorf
End of News                                     DGAP News-Service
---------------------------------------------------------------------------